EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate

On Thursday, Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent.

The patent, once issued, will expand Adial’s intellectual property protection around its lead investigational drug, AD04, which is designed to treat alcohol use disorder (AUD).

Also Read: EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder.

The new patent covers additional genotype combinations identified through the company’s proprietary genetic diagnostic tool, further enhancing the precision medicine approach of AD04.

“This Notice of Allowance represents an important milestone for Adial as we continue to broaden our patent estate,” said Cary Claiborne, CEO of Adial Pharmaceuticals.

AD04 is the company’s lead investigational new drug product, a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the ONWARD Phase 3 trial for the potential treatment of AUD in subjects with certain target genotypes identified using the company’s proprietary companion diagnostic genetic test.

In August, Adial Pharmaceuticals announced that the final patient completed the last dose in the pharmacokinetics study of AD04 for Alcohol Use Disorder (AUD) in heavy drinking patients (defined as <10 drinks/drinking day). Topline results are expected to be announced during the fourth quarter of 2024.

In April, Adial Pharmaceuticals announced a new US patent, expanding Adial’s intellectual property protection and covering the combination of the company’s proprietary genetic diagnostic to identify patients with specific genotypes for AUD and other drug dependencies.

Price Action: ADIL stock closed at $1.03 on Wednesday.